Methadone as First-line Opioid for the Management of Cancer Pain
| Autor: | Mercadante, Sebastiano, Adile, Claudio, Ferrera, Patrizia, Pallotti, Maria Caterina, Ricci, Marianna, Bonanno, Giuseppe, Casuccio, Alessandra |
|---|---|
| Přispěvatelé: | Mercadante, Sebastiano, Adile, Claudio, Ferrera, Patrizia, Pallotti, Maria Caterina, Ricci, Marianna, Bonanno, Giuseppe, Casuccio, Alessandra |
| Rok vydání: | 2022 |
| Předmět: | |
| Zdroj: | The Oncologist. 27:323-327 |
| ISSN: | 1549-490X 1083-7159 |
| DOI: | 10.1093/oncolo/oyab081 |
| Popis: | Aim The aim of this study was to assess the efficacy and adverse effects of methadone when used as first-line therapy in patients that are either receiving low doses of opioids or none. Methods Patients with advanced cancer were prospectively assessed. Opioid-naive patients (L-group) were started with methadone at 6 mg/day. Patients receiving weak or other opioids in doses of Results Eighty-two patients were assessed. In both groups H and L, there were significant changes in pain and symptom intensity at the different times during the study. Adverse effects as causes of drop-out were minimal. Mean MEImg was 0.09 (SD 0.28) and 0.02 (SD 0.07) at T30 and T60, respectively. MEI% was 1.01 (SD 3.08) and 0.27 (SD 0.86) at T30 and T60, respectively. Conclusion Methadone used as a first-line opioid therapy provided good analgesia with limited adverse effects and a minimal opioid-induced tolerance. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|